These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 22551904)

  • 1. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
    Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ
    J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
    Peng Y; Li Z; Zhang S; Xiong Y; Cun Y; Qian C; Li M; Ren T; Xia L; Cheng Y; Wang D
    Int J Cancer; 2014 Dec; 135(11):2687-96. PubMed ID: 24729390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
    Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
    Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.
    Erčulj N; Kovač V; Hmeljak J; Franko A; Dodič-Fikfak M; Dolžan V
    J Thorac Oncol; 2012 Oct; 7(10):1609-17. PubMed ID: 22982660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
    Xu C; Wang X; Zhang Y; Li L
    Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):912-7. PubMed ID: 22152690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Yuan P; Liu L; Wu C; Zhong R; Yu D; Wu J; Xu Y; Nie S; Miao X; Sun Y; Xu B; Lin D
    Cancer Biol Ther; 2010 Nov; 10(9):854-9. PubMed ID: 20814250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.
    Ke HG; Li J; Shen Y; You QS; Yan Y; Dong HX; Liu JH; Shen ZY
    Asian Pac J Cancer Prev; 2012; 13(9):4413-6. PubMed ID: 23167352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
    Mlak R; Krawczyk P; Ramlau R; Kalinka-Warzocha E; Wasylecka-Morawiec M; Wojas-Krawczyk K; Kucharczyk T; Homa I; Kozioł P; Ciesielka M; Chudziak D; Milanowski J
    Oncol Rep; 2013 Nov; 30(5):2385-98. PubMed ID: 23982437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
    Joerger M; Burgers SA; Baas P; Smit EF; Haitjema TJ; Bard MP; Doodeman VD; Smits PH; Vincent A; Huitema AD; Beijnen JH; Schellens JH
    Cancer; 2012 May; 118(9):2466-75. PubMed ID: 22031394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.
    Chen J; Zhao QW; Shi GM; Wang LR
    J Zhejiang Univ Sci B; 2012 Nov; 13(11):875-83. PubMed ID: 23125080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy.
    Li D; Zhou Q; Liu Y; Yang Y; Li Q
    Med Oncol; 2012 Sep; 29(3):1622-8. PubMed ID: 21805378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
    Han B; Guo Z; Ma Y; Kang S; Wang Y; Wei Q; Wu X
    Int J Clin Exp Pathol; 2015; 8(4):4113-9. PubMed ID: 26097600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
    Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
    Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
    Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
    Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
    J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients.
    Wang S; Wang J; Bai Y; Wang Q; Liu L; Zhang K; Hong X; Deng Q; Zhang X; He M; Wu T; Xu P; Guo H
    Cancer Med; 2016 Sep; 5(9):2332-42. PubMed ID: 27465648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.
    Cui Z; Yin Z; Li X; Wu W; Guan P; Zhou B
    BMC Cancer; 2012 Feb; 12():71. PubMed ID: 22339849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.